Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology firm focused on the cure of metastatic and primary liver cancers, reported that subjects treatment and data collection for the ICC cohort of its European Phase II HCC/ICC trial is ongoing. It will announce interim report for the cohort once the information is fully mature.
Moreover, the firm considers that the original objective to obtain an efficacy indication for the Phase II ICC cohort has been met by the report of multicenter patient outcomes noted in the retrospective information collection of their commercial ICC cases performed by their European investigators. These positive observations and outcomes were discussed with KOL at a Delcath-planned medical advisory panel meeting and resulted in the agreement that PHP® treatment does, indeed, show an efficacy indication in ICC and is good candidate of full clinical investigation.
The details
Delcath Systems has accepted an invitation from the CCF to present its preliminary research plans for application of PHP® therapy in the cure of ICC. The CCF is the leading patient advocacy firm devoted to finding a treatment and improving the life quality for patients with cholangiocarcinoma.
Company representatives will showcase a summary of European investigator results and its clinical advancement plans for ICC to the medical advisory board at the upcoming CCF Annual Meeting, to be held from February 1-3, 2017. Delcath will even offer a sponsorship grant to back the work of the CCF as part of its contribution in the CCF Annual Meeting.
Jennifer K. Simpson, Ph.D., the CEO and President of Delcath, said that though the interim report they projected for ICC cohort in their Phase 2 study in HCC/ICC is not yet available. The milestones for this trial have largely been met by the independent retrospective assessment performed by their European investigators.
The promising observations and outcomes noted at their international KOL forum last year offered them with considerable confidence in the prospect of their treatment in the ICC tumor type and assisted for their initial research plan.
THE MORNING REPORT
Start your workday the right way with the news that matters most.
Your information is 100% secure with us and will never be shared Disclaimer & Privacy Policy
